Financing ·
Zenas BioPharma terminates $200M ATM program with $46.8M remaining after selling $153.2M
ZBIOZenas BioPharma, Inc.
Zenas BioPharma terminated its existing at-the-market (ATM) equity offering program, which had an aggregate capacity of $200 million. The company has sold approximately $153.2 million in shares under the prior prospectus supplement, leaving $46.8 million unsold. On November 6, 2026, Zenas filed a new prospectus supplement to establish a replacement ATM program with the same $200 million aggregate offering price limit through Jefferies LLC as sales agent. The company operates in the biopharmaceutical industry, focusing on developing therapies for rare diseases.